Cargando…

Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer

Targeted therapies have revolutionized the treatment for many patients with non-small cell lung cancer (NSCLC). Multiple new oral targeted therapies have been approved in the last decade; however, their overall efficacy may be reduced by poor adherence, treatment interruptions, or dose reductions du...

Descripción completa

Detalles Bibliográficos
Autores principales: Hines, Jacobi B., Bowar, Benjamin, Levine, Emma, Esposito, Alessandra, Garassino, Marina C., Bestvina, Christine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253830/
https://www.ncbi.nlm.nih.gov/pubmed/37298380
http://dx.doi.org/10.3390/ijms24119429
_version_ 1785056499908739072
author Hines, Jacobi B.
Bowar, Benjamin
Levine, Emma
Esposito, Alessandra
Garassino, Marina C.
Bestvina, Christine M.
author_facet Hines, Jacobi B.
Bowar, Benjamin
Levine, Emma
Esposito, Alessandra
Garassino, Marina C.
Bestvina, Christine M.
author_sort Hines, Jacobi B.
collection PubMed
description Targeted therapies have revolutionized the treatment for many patients with non-small cell lung cancer (NSCLC). Multiple new oral targeted therapies have been approved in the last decade; however, their overall efficacy may be reduced by poor adherence, treatment interruptions, or dose reductions due to adverse events. Most institutions lack standard monitoring protocols for toxicities from these targeted agents. This review describes important adverse events observed in clinical trials and reported by the U.S. Food and Drug Administration for both currently approved and upcoming promising therapies in the treatment of NSCLC. These agents cause a range of toxicities, including dermatologic, gastroenteric, pulmonary, and cardiac toxicities. This review proposes protocols for routine monitoring of these adverse events, both prior to initiation of therapy and while on treatment.
format Online
Article
Text
id pubmed-10253830
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102538302023-06-10 Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer Hines, Jacobi B. Bowar, Benjamin Levine, Emma Esposito, Alessandra Garassino, Marina C. Bestvina, Christine M. Int J Mol Sci Review Targeted therapies have revolutionized the treatment for many patients with non-small cell lung cancer (NSCLC). Multiple new oral targeted therapies have been approved in the last decade; however, their overall efficacy may be reduced by poor adherence, treatment interruptions, or dose reductions due to adverse events. Most institutions lack standard monitoring protocols for toxicities from these targeted agents. This review describes important adverse events observed in clinical trials and reported by the U.S. Food and Drug Administration for both currently approved and upcoming promising therapies in the treatment of NSCLC. These agents cause a range of toxicities, including dermatologic, gastroenteric, pulmonary, and cardiac toxicities. This review proposes protocols for routine monitoring of these adverse events, both prior to initiation of therapy and while on treatment. MDPI 2023-05-29 /pmc/articles/PMC10253830/ /pubmed/37298380 http://dx.doi.org/10.3390/ijms24119429 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hines, Jacobi B.
Bowar, Benjamin
Levine, Emma
Esposito, Alessandra
Garassino, Marina C.
Bestvina, Christine M.
Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer
title Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer
title_full Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer
title_fullStr Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer
title_full_unstemmed Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer
title_short Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer
title_sort targeted toxicities: protocols for monitoring the adverse events of targeted therapies used in the treatment of non-small cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253830/
https://www.ncbi.nlm.nih.gov/pubmed/37298380
http://dx.doi.org/10.3390/ijms24119429
work_keys_str_mv AT hinesjacobib targetedtoxicitiesprotocolsformonitoringtheadverseeventsoftargetedtherapiesusedinthetreatmentofnonsmallcelllungcancer
AT bowarbenjamin targetedtoxicitiesprotocolsformonitoringtheadverseeventsoftargetedtherapiesusedinthetreatmentofnonsmallcelllungcancer
AT levineemma targetedtoxicitiesprotocolsformonitoringtheadverseeventsoftargetedtherapiesusedinthetreatmentofnonsmallcelllungcancer
AT espositoalessandra targetedtoxicitiesprotocolsformonitoringtheadverseeventsoftargetedtherapiesusedinthetreatmentofnonsmallcelllungcancer
AT garassinomarinac targetedtoxicitiesprotocolsformonitoringtheadverseeventsoftargetedtherapiesusedinthetreatmentofnonsmallcelllungcancer
AT bestvinachristinem targetedtoxicitiesprotocolsformonitoringtheadverseeventsoftargetedtherapiesusedinthetreatmentofnonsmallcelllungcancer